Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells

BMC Cancer

Volumn 3, Issue , 2003, Pages

  Konnikova, Liza ^a   Kotecki, Maciej ^a   Kruger, Mathew M ^a   Cochran, Brent H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL XL; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; BIRC5 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; STAT3 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR PROTEIN;

ANALYTIC METHOD; APOPTOSIS; ASTROCYTE; ASTROCYTOMA; BIOCHEMISTRY; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; REVIEW; RNA INTERFERENCE; TUMOR CELL; ARTICLE; DOWN REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; ASTROCYTES; ASTROCYTOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 3042748279     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-3-23     Document Type: Review

References (62)

1. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001, 15:1311-1333.
2. Rasheed BK, Wiltshire RN, Bigner SH and Bigner DD: Molecular pathogenesis of malignant gliomas. Curr Opin Oncol 1999, 11:162-167.
3. Prados MD and Levin V: Biology and treatment of malignant glioma. Semin Oncol 2000, 27:1-10.
4. Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000, 97:6242-6244.
5. Wechsler-Reya R and Scott MP: The developmental biology of brain tumors. Annu Rev Neurosci 2001, 24:385-428.
6. Levin V A S. Leivei, P. H. Gutin: Neoplasms of the central nervous system In Cancer: Principles and practice of oncology. Edited by: V T DeVita S J Hellman SA Rosemberg. Philadelphia, Lippincott-Raven; 1997:2022-2082.
7. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A and Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
9. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362.
10. Ivanchuk SM, Mondal S, Dirks PB and Rutka JT: The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001, 51:219-229.
11. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A and Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000, 60:417-424.
12. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS and Collins VP: Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996, 56:5141-5145.
13. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994, 54:6321-6324.
14. Ihle JN: STATs: Signal transducers and activators of transcription (review). Cell 1996, 84:331-334.
15. Shuai K, Schindler C, Prezioso VR and Darnell J. E., Jr.: Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992, 258:1808-1812.
16. Schindler C, Shuai K, Prezioso VR and Darnell J. E., Jr.: Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992, 257:809-813.
17. Shuai K, Stark GR, Kerr IM and Darnell J. E., Jr.: A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
18. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D and Darnell J. E., Jr.: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell 1994, 76:821-828.
19. Hayes TE, Kitchen AM and Cochran BH: Inducible binding of a factor to the c-fos regulatory region. Proc Natl Acad Sci U S A 1987, 84:1272-1276.
20. Schindler C, Fu XY, Improta T, Aebersold R and Darnell J. E., Jr.: Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha. Proc Natl Acad Sci U S A 1992, 89:7836-7839.
21. Wagner BJ, Hayes TE, Hoban CJ and Cochran BH: The SIF binding element confers sis/PDGF inducibility onto the c-fos promoter. Embo J 1990, 9:4477-4484.
22. Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell J. E., Jr. and Levy DE: Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol 1992, 12:3315-3324.
23. Stocklin E, Wissler M, Gouilleux F and Groner B: Functional interactions between Stat5 and the glucocorticoid receptor. Nature 1996, 383:726-728.
24. Ehret GB, Reichenbach P, Schindler U, Horvath CM, Fritz S, Nabholz M and Bucher P: DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 2001, 276:6675-6688.
25. Takeda K and Akira S: STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 2000, 11:199-207.
26. Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556.
27. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F and Graeve L: Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998, 334 ( Pt 2):297-314.
28. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T and Yokota T: STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. Embo J 1999, 18:4261-4269.
29. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 2002, 109:1139-1142.
30. Zhong Z, Wen Z and Darnell J. E., Jr.: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
31. Rajan P and McKay RD: Multiple routes to astrocytic differentiation in the CNS. J Neurosci 1998, 18:3620-3629.
32. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
33. Bowman T, Garcia R, Turkson J and Jove R: STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
34. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y and Kim JD: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000, 97:4227-4232.
35. Schuringa JJ, Wierenga AT, Kruijer W and Vellenga E: Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 2000, 95:3765-3770.
36. Badache A and Hynes NE: Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 2001, 61:383-391.
37. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8:945-954.
38. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP and Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18:2545-2552.
39. Bromberg JF, Horvath CM, Besser D, Lathem WW and Darnell J. E., Jr.: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998, 18:2553-2558.
40. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J and Jove R: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002, 62:6659-6666.
41. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
42. Elbashir SM Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplex of 21-nucleotide RNAs mediate RNA interfeerence in cultured mammalian cells. Nature 2001, 411:494-498.
43. Elstein KH and Zucker RM: Comparison of cellular and nuclear flow cytometric techniques for discriminating apoptotic subpopulations. Exp Cell Res 1994, 211:322-331.
44. Chan A, Reiter R, Wiese S, Fertig G and Gold R: Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models. Histochem Cell Biol 1998, 110:553-558.
45. Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S and Matsuzawa Y: STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. Int J Cancer 1998, 78:326-330.
46. Aoki Y, Feldman GM and Tosato G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101:1535-1542.
47. Martin S, Toquet C, Oliver L, Cartron PF, Perrin P, Meflah K, Cuillere P and Vallette FM: Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neurooncol 2001, 52:129-139.
48. Kleinschmidt-DeMasters BK, Heinz D, McCarthy PJ, Bobak JB, Lillehei KO, Shroyer AL and Shroyer KR: Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. Arch Pathol Lab Med 2003, 127:826-833.
49. Li W, Liang X, Kellendonk C, Poli V and Taub R: STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 2002, 277:28411-28417.
50. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R and Yu H: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999, 59:5059-5063.
51. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell J. E., Jr.: Stat3 as an oncogene. Cell 1999, 98:295-303.
52. Cattaneo E, Magrassi L, De-Fraja C, Conti L, Di Gennaro I, Butti G and Govoni S: Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res 1998, 18:2381-2387.
53. Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R and Wharen R: Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer 2003, 104:19-27.
54. Tchirkov A, Rolhion C, Bertrand S, Dore JF, Dubost JJ and Verrelle P: IL-6 gene amplification and expression in human glioblastomas. Br J Cancer 2001, 85:518-522.
55. Riffkin CD, Gray AZ, Hawkins CJ, Chow CW and Ashley DM: Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro-oncol 2001, 3:229-240.
56. Rieger J, Ohgaki H, Kleihues P and Weller M: Human astrocytic brain tumors express AP02L/TRAIL. Acta Neuropathol (Berl) 1999, 97:1-4.
57. Das A, Tan WL, Teo J and Smith DR: Expression of survivin in primary glioblastomas. J Cancer Res Clin Oncol 2002, 128:302-306.
58. O'Driscoll L, Linehan R and Clynes M: Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets 2003, 3:131-152.
59. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
60. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA and Herweijer H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002, 32:107-108.
61. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ and Kay MA: RNA interference in adult mice. Nature 2002, 418:38-39.
62. Makimura H, Mizuno TM, Mastaitis JW, Agami R and Mobbs CV: Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 2002, 3:18.